Smith & Nephew reveals collusion attempt
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew discloses July 31 that one of its independent sales representatives sent an email Oct. 28, 2005, to competitors seeking cooperation on pricing for hip and knee implants. The London-based firm, which has since severed its relationship with the rep, denies authorizing or acting upon the email. The price-fixing scheme likely prompted an investigation by the U.S. Department of Justice, which subpoenaed Smith & Nephew, Stryker, Johnson & Johnson/DePuy, Biomet and Zimmer in June for documents related to possible antitrust violations (1"The Gray Sheet" July 3, 2006, p. 8). A separate investigation by the U.S. attorney's office in Newark, N.J., pertaining to the relationship between orthopedics manufacturers and physicians is ongoing (2"The Gray Sheet" April 4, 2005, p. 3)...
You may also be interested in...
DoJ Probes Big Orthopedic Firms’ Pricing, Deflating Investor Confidence
The U.S. Department of Justice served subpoenas to the five largest orthopedic manufacturers to investigate suspected industry violations of antitrust laws in pricing hip and knee implants. The specific nature of the inquiry is unknown
DoJ Probe Into Orthopedic Industry Could Rattle Upward Pricing Trend
Several subpoenas of orthopedic manufacturers by the U.S. attorney's office in Newark, N.J. appear to be aimed at alleviating pricing pressure on hospitals for orthopedic devices
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip